[go: up one dir, main page]

DE602006016106D1 - Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung - Google Patents

Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung

Info

Publication number
DE602006016106D1
DE602006016106D1 DE602006016106T DE602006016106T DE602006016106D1 DE 602006016106 D1 DE602006016106 D1 DE 602006016106D1 DE 602006016106 T DE602006016106 T DE 602006016106T DE 602006016106 T DE602006016106 T DE 602006016106T DE 602006016106 D1 DE602006016106 D1 DE 602006016106D1
Authority
DE
Germany
Prior art keywords
compositions
markers
treatment
predicting
output
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006016106T
Other languages
English (en)
Inventor
Kirsten Vang Nielsen
Bent Laursen Eilertsen
Tim Svenstrup Poulsen
Henning T Mouridsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dako Denmark ApS
Original Assignee
Dako Denmark ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dako Denmark ApS filed Critical Dako Denmark ApS
Publication of DE602006016106D1 publication Critical patent/DE602006016106D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G01N33/57557
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
DE602006016106T 2005-05-31 2006-05-30 Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung Active DE602006016106D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68607005P 2005-05-31 2005-05-31
PCT/DK2006/000300 WO2006128463A2 (en) 2005-05-31 2006-05-30 Compositions and methods for predicting outcome of treatment

Publications (1)

Publication Number Publication Date
DE602006016106D1 true DE602006016106D1 (de) 2010-09-23

Family

ID=35809661

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006016106T Active DE602006016106D1 (de) 2005-05-31 2006-05-30 Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung

Country Status (6)

Country Link
US (1) US8679746B2 (de)
EP (1) EP1885878B1 (de)
AT (1) ATE477339T1 (de)
DE (1) DE602006016106D1 (de)
ES (1) ES2350648T3 (de)
WO (1) WO2006128463A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009154669A1 (en) * 2008-05-28 2009-12-23 Albert Einstein College Of Medicine Of Yeshiva University Prediction of chemotherapeutic response via single-cell profiling of transcription site activation
EP3216874A1 (de) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Verfahren zum stratifizieren und annotieren der behandlungsoptionen eines krebsmedikaments
EP2446053A1 (de) * 2009-05-29 2012-05-02 Ventana Medical Systems, Inc. Verfahren zur zählung der genkopiezahl in einer biologischen probe mittels in-situ-hybrdisierung
US9309556B2 (en) 2010-09-24 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
US9556473B2 (en) * 2011-02-15 2017-01-31 Leica Biosystems Newcastle Ltd Methods for identifying nucleic acid sequences
CN106338423B (zh) 2015-07-10 2020-07-14 三斯坎公司 组织学染色的空间复用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004004571T2 (de) 2003-08-28 2007-11-08 Roche Diagnostics Gmbh Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase

Also Published As

Publication number Publication date
US8679746B2 (en) 2014-03-25
EP1885878A2 (de) 2008-02-13
US20090042187A1 (en) 2009-02-12
WO2006128463A2 (en) 2006-12-07
EP1885878B1 (de) 2010-08-11
WO2006128463A3 (en) 2007-02-15
ES2350648T3 (es) 2011-01-25
ATE477339T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
EP1945754A4 (de) Zusammensetzungen und verfahren zur behandlung und diagnostizierung von krebs
ATE523525T1 (de) Anti-tumorassoziiertes antigen tat10772 zum nachweis und behandlung von krebs
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
IL258880A (en) Diarylhydantoin compounds
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
EP2125855A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs und anderen krankheiten
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
EP1663259A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
EA200870391A1 (ru) Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
UA100007C2 (ru) Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
ATE432924T1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
EP2141989A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
BRPI0514586A (pt) triazolftalazinas
TW200626900A (en) Wnt proteins and detection and treatment of cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
DE602006016106D1 (de) Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung